Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 5

Results For "Chairman"

834 News Found

Granules India completes acquisition of Senn Chemicals
News | April 11, 2025

Granules India completes acquisition of Senn Chemicals

Strengthening capabilities in Peptide Therapeutics and CDMO services


Briefs: AstraZeneca Pharma India, Pharmaids and Dr. Agarwal's Health Care
News | April 01, 2025

Briefs: AstraZeneca Pharma India, Pharmaids and Dr. Agarwal's Health Care

AstraZeneca Pharma India discontinues manufacturing of Imdur


NCLT approves amalgamation of Cohance Lifesciences into and with Suven Pharmaceuticals
News | April 01, 2025

NCLT approves amalgamation of Cohance Lifesciences into and with Suven Pharmaceuticals

The amalgamation is expected to create a future-ready, diversified CDMO platform with a technology-led focus across three high-growth verticals-Antibody Drug Conjugates


J&J to break ground on new biologics facility in North Carolina
News | March 24, 2025

J&J to break ground on new biologics facility in North Carolina

New facility will support plans to advance J&J’s portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases


Zota Health Care expands Davaindia network to 1,530 stores
Healthcare | March 20, 2025

Zota Health Care expands Davaindia network to 1,530 stores

The company has also launched its first three 24*7 pharmacy stores via COCO model in Bengaluru


Aster DM Healthcare promoters reduce share pledge from 99% to 41%
News | March 12, 2025

Aster DM Healthcare promoters reduce share pledge from 99% to 41%

The new lenders – JP Morgan, HSBC, and Barclays provided fresh funding


Zota Health Care launched B2C online portal ‘davaindia’
Healthcare | March 11, 2025

Zota Health Care launched B2C online portal ‘davaindia’

This e-commerce platform is launched as a hyperlocal model


Sun Pharma to acquire Nasdaq-listed Checkpoint Therapeutics
News | March 10, 2025

Sun Pharma to acquire Nasdaq-listed Checkpoint Therapeutics

Will add UNLOXCYT (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) to Sun Pharma's global onco-derm franchise